Avid Radiopharmaceuticals is developing new molecular imaging agents capable of changing the medical management of significant chronic human diseases, allowing early treatment and management of people at risk before symptoms of disease can develop. Avid’s pipeline of imaging compounds has the potential to dramatically alter the clinical course of Alzheimer’s disease, Dementia with Lewy Bodies,…
Clinipace Worldwide, a global digital clinical research organization that has pioneered technology-amplified contract research services, specializes in fully-integrated clinical research services for biopharmaceutical and medical device firms. Optimized by TEMPO™, its proprietary eClinical platform, the Clinipace team of experts brings extensive knowledge and insight into site selection, patient recruitment, clinical operations, data management, medical monitoring,…
Delfi Diagnostics is focused on detecting and locating early cancer through blood testing. Cell-free DNA breaks into fragments in the bloodstream and carries many clues about whether a person may have early-stage cancer. Delfi applies advanced machine-learning methods to accurately detect cancer from these fragments and also determine where in the body the tumor has…
Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single molecule resolutions, advancing beyond the decades old technologies based on mass spectrometry and ELISAs. The Glyphic platform will enable the development of novel therapeutics and diagnostics and, ultimately, a deeper understanding of human biology. The company was founded by…
Guardant Health is a leading precision oncology company that combines proprietary blood tests with vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed improve clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based…
Sera Prognostics is developing diagnostic tests that use proprietary biomarkers that are predictive of preterm birth, preeclampsia and other pregnancy complications. Sera aims to improve the health and development of children through early assessment of pregnancy complications that can guide medical interventions and lead to healthier deliveries. NASDAQ: SERA